Regulation - GlaxoSmithKline, Metabolics

Filter

Current filters:

GlaxoSmithKlineMetabolics

Popular Filters

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20-02-2012

Finalizing its review on orlistat-containing medicines and the possible risk of severe liver injuries,…

AlliBayerBiotechnologyCardio-vascularCell TherapeuticsEuropeGlaxoSmithKlineMetabolicsOncologyorlistatPharmaceuticalPixuvriRegulationRocheTrasylolXenical

Parexel

Parexel

Back to top